- Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
-
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Keiichi K, Kondo E, Sugiyama T, Tabata T
- KMID: 2526299
- J Gynecol Oncol.
- 2021 Jan;32(1):e9.
- doi: 10.3802/jgo.2021.32.e9
Objective: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains... -
- CITED
-
- Close
- SHARE
-
- Close
